Literature DB >> 2917184

Inhibition and complexation of activated protein C by two major inhibitors in plasma.

M J Heeb1, F España, J H Griffin.   

Abstract

To determine the major physiologic inhibitors of activated protein C (APC), plasma was incubated with APC or with Protac C and subjected to immunoblotting. APC:inhibitor complexes gave two major bands reacting with antiprotein C antibodies when immunoblotted on nondenaturing gels, and additional minor bands that varied between serum and plasma. Formation of one of the two major bands of APC:inhibitor complex, but not the other, was stimulated by heparin and only this band reacted with antibodies to the previously described APC inhibitor that is here designated PCI-1. Plasma immunodepleted of PCI-1 formed complexes with APC as visualized with antiprotein C but not anti-PCI-1 antibodies, and exhibited heparin-independent inhibition of APC activity, providing evidence for the existence of a second major physiologic APC inhibitor, PCI-2. Formation of APC:PCI-2 complexes in PCI-1-depleted plasma paralleled inhibition of APC amidolytic activity. PCI-2 was separated from PCI-1 and partially purified using column chromatography. PCI-2 formed inactive complexes of approximately 110,000 molecular weight (mol wt) with APC suggesting PCI-2 has an approximate mol wt of 50,000. Thus, inhibition of APC in plasma involves two major distinct 50,000 mol wt inhibitors, the heparin-dependent PCI-1 and the heparin-independent PCI-2.

Entities:  

Mesh:

Substances:

Year:  1989        PMID: 2917184

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  8 in total

1.  Post varicella disseminated intravascular coagulation and transient protein S deficiency in an otherwise healthy 6-year-old boy: a case report.

Authors:  V Wiegering; G Balling; J Wirbelauer; A Sturm; H J Girschick
Journal:  Infection       Date:  2010-09-16       Impact factor: 3.553

2.  Comparative effects of the human protein C activator, Protac, on the activated partial thromboplastin clotting times of plasmas, with special reference to the dog.

Authors:  I B Johnstone; C A Martin
Journal:  Can J Vet Res       Date:  2000-04       Impact factor: 1.310

3.  Models of the serine protease domain of the human antithrombotic plasma factor activated protein C and its zymogen.

Authors:  C L Fisher; J S Greengard; J H Griffin
Journal:  Protein Sci       Date:  1994-04       Impact factor: 6.725

4.  α2-Macroglobulin Is a Significant In Vivo Inhibitor of Activated Protein C and Low APC:α2M Levels Are Associated with Venous Thromboembolism.

Authors:  Laura Martos; Luis Andrés Ramón; Julia Oto; Álvaro Fernández-Pardo; Santiago Bonanad; Ana Rosa Cid; Andras Gruber; John H Griffin; Francisco España; Silvia Navarro; Pilar Medina
Journal:  Thromb Haemost       Date:  2018-02-15       Impact factor: 5.249

5.  Drotrecogin alfa (activated).

Authors:  Katherine A Lyseng-Williamson; Caroline M Perry
Journal:  Drugs       Date:  2002       Impact factor: 9.546

6.  [The clinical importance of protein C and S deficiency for surgical patients].

Authors:  H Rabl; H Fruhwirth
Journal:  Langenbecks Arch Chir       Date:  1992

7.  Species-specific anticoagulant and mitogenic activities of murine protein S.

Authors:  José A Fernández; Mary J Heeb; Xiao Xu; Itender Singh; Berislav V Zlokovic; John H Griffin
Journal:  Haematologica       Date:  2009-10-08       Impact factor: 9.941

8.  Is protein C inhibitor antithrombotic and protective in pulmonary hypertension?

Authors:  L M Beaulieu; F C Church
Journal:  J Thromb Haemost       Date:  2006-09-15       Impact factor: 16.036

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.